INTRODUCTION
Differentiated thyroid malignancy is the most common endocrine malignancy. The incidence of thyroid cancer is rising faster than any other malignancy in both men and women. Suppression of TSH is a mainstay of clinical thyroid cancer management, whether TSH exerts an influence on development of human thyroid cancer remains uncertain. The reasons for the observed increase in incidence have been widely debated and include enhanced detection of subclinical thyroid cancer due to the growing use of diagnostic imaging and exposure to a number of environmental factors. 1 Thyroid cancer often presents as a solitary nodule or as a part of a multinodular goiter. This creates an important clinical dilemma as thyroid nodules are very common in 50-67% of the population, and more than 90% are benign.
Although incidental thyroid neoplasm have long been recognized due to their presence during post-mortem examinations, there is a significant and increasing clinical burden associated with detecting this disease in patients 3 , for whom the differentiation between aggressive and indolent diagnoses is crucial. 4 There are a number of well-established and evolving clinical tools to discern malignant from benign thyroid nodules. 5 Most international guidelines recommend the use of a combination of diagnostic tools, including measurement of thyroid-stimulating hormone (TSH) to assess functional thyroid status, high resolution ultrasonography (US) scanning to assess the morphological characteristics of the thyroid and nodule(s) and fine needle aspiration for cytological evaluation of the presence of malignancy. 6, 7 Current guidelines recommend the medium-to-long-term use of TSH suppression in high-risk thyroid cancer but not in lower-risk tumours because of the health risks associated with the induction of subclinical and overt thyrotoxicosis.
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METHODS
From September 2017-September 2018. This is a combined retrospective and prospective study conducted for studying euthyroid patients who had thyroidectomy for benign thyroid disease and differentiated thyroid cancer retrospectively by collecting data about preoperative TSH level, and the prospective part of the study was done by observing preoperative TSH level in patients undergo thyroidectomy for benign and malignant thyroid disorders then exclude patients with undifferentiated thyroid cancer and medullary carcinoma.
Adult patient at different age and gender with normal TSH level; euthyroid patients that diagnosed as differentiated thyroid cancer (follicular and papillary) and other benign thyroid conditions as well as euthyroid patient with any thyroid diseases who will going to have thyroidectomy were included in this study.
Patients with undifferentiated thyroid cancer or medullary carcinoma; in addition to those with abnormal TSH level (Graves' disease, thyrotoxicosis, hashimotoo thyroiditis) as well as patients on thyroxin were excluded from this study.
Data were analyzed using IBM SPSS software package version 20.0 (Belmont, Calf, 2013). Data were collected in tables then analyzed in regarding to Chi square (x 2 ) and p value less than 0.05 were considered significant.
RESULTS
This study of cases of thyroid swelling conducted at the surgical department in the Damanhour Teaching Hospital and Menoufia University Hospital and included retrospective study of 192 cases (Group I) with prospective study included 55 cases (Group II).
The age of group I ranged between 17-85 years. In this group the age of benign cases ranged between 17-57 years while in malignant cases ranged between 27-85 years and the statistical analysis revealed a significant increase in the age of malignant cases than that of benign cases in this group (p=0.021) ( Table 1 ).
The age of group II ranged between 20-76 years. In this group the age of benign cases ranged between 21-67 years while in malignant cases ranged between 20-67 years and the statistical analysis revealed no significant difference between the age of malignant and benign cases in this group (p=0.385) ( Table 1 ). In cases of group II; histopathologic examination of the specimen revealed 29 patients of this group of benign nature all of them were multinodular goiter (29/29, 100%), (Table 4 ). While this group had 26 cases of malignant lesion on histopathologic examination 21 of them (80.8%) were papillary carcinoma while five cases were follicular carcinoma (19.2%) and statistical analysis revealed the predominance of papillary carcinoma in malignant cases of this group (p=0.01) ( Table 4 ). Table 5) .
In group II, The TSH level ranged between 0.51-5.01 with a mean value of 1.95±1.14. In this group the level in benign cases ranged between 0.51-4.62 with a mean value of 1.59±0.85 while in malignant cases it ranged between 0.73-5.01 with a mean of 2.36±1.1 and the statistical analysis revealed a significant increase in the serum level of TSH in malignant cases than in benign cases in this group (p=0.01) ( Table 5 ).
DISCUSSION
Our study revealed that the age was older in malignant cases and females were commonly affected than males which is similar to the results of Santosh et al, Borsaikia and Patar and Halbhavi et al. [8] [9] [10] Neck swelling was the main presenting symptom in our cases which was mainly nodular with little cases of smooth swelling which was in agreement with Santosh et al, Borsaikia and Patar and Halbhavi et al. [8] [9] [10] The histopathologic examination of our cases revealed that the most common benign thyroid swelling was multinodular goiter followed by thyroid adenoma while the most common malignant thyroid swelling was papillary carcinoma followed by follicular carcinoma. Tamhane and Gharib, revealed in their study that the most common malignant carcinoma was the papillary carcinoma (97-99%) and follicular carcinoma constitute about little percentage which agreed with our results.
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Also, Hirachand et al, found in their study that the most common lesion in the thyroid gland was colloid goiter. 12 Among the malignant neoplasms the commonest was papillary carcinoma which coincides with our results.
Our results disagree with what found by Santosh et al, were he revealed in their study that only 10% of cases of malignant and Halbhavi et al, who found also only 10.3% of his cases belonged to malignant group. 8, 10 As well as Borsaikia and Patar, who found that follicular carcinoma (4.24%) was more commonly than papillary carcinoma (1.41%). 9 Our results revealed increase serum level of TSH in malignant cases than in benign cases and this was agree with what reported by Tamhane and Gharib in their study that Boelaert et al, and Haymart et al, where they concluded in their studies that increased serum TSH or TSH even in the upper limit of normal is associated with increased risk and advanced stage of malignancy which. 13, 14 Also, Gharib et al, documented in their study that Gerschpacher et al, concluded in his study that suppressed or low levels of thyrotropin (TSH) are associated with a decreased probability of malignancy, whereas increased levels of serum TSH, even when the levels are still within reference limits, are statistically associated with an increased risk of cancer in thyroid nodular disease. 15, 16 
CONCLUSION
From our study we can conclude that: TSH level can be taken as an indicator for malignant transformation of thyroid swelling and also we recommend to do FNAC biopsy for any thyroid swelling that showed elevated level of serum TSH to its upper normal level for early detection of thyroid malignant tumors.
